Alzheimer%s Disease Therapeutics and Diagnostics: Global Markets - NewsOn6.com - Tulsa, OK - News, Weather, Video and Sports - KOTV.com |

Alzheimer%s Disease Therapeutics and Diagnostics: Global Markets

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ReportBuyer

NEW YORK, June 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Alzheimer%s Disease Therapeutics and Diagnostics: Global Markets

http://www.reportbuyer.com/pharma_healthcare/diseases/alzheimer/alzheimers_disease_therapeutics_diagnostics_global_markets.html

INTRODUCTION

STUDY GOALS AND OBJECTIVES

BCC's goal in conducting this study was to determine the current status of Alzheimer's disease treatments and diagnostics and assess the growth potential of this area over a 5-year period, from 2012 to 2017.

Our key objective was to present a comprehensive analysis of the current pipeline of therapeutic and diagnostic technologies, analyze the market and forecast for Alzheimer's therapeutics and diagnostics, along with outlining the key factors that will influence this therapeutic area in the next few years.

REASONS FOR DOING THIS STUDY

Alzheimer's disease is becoming an increasingly difficult challenge to caregivers, families and the healthcare industry as the number of patients climb and the frustration with lack of effective treatments grows. Though there are a number of marketed drugs approved for AD, this remains a significant area of unmet medical need. Clinical success has proven elusive; however, there are now numerous companies developing novel treatments. This report will review the programs in development and quantify the market opportunities in AD. This study aims to quantify where this market is heading and where the opportunities may lie.

SCOPE OF REPORT

The scope of this report is on the pharmaceutical segment, diagnostics and imaging modalities. We have compiled a study of the market, and current and emerging modes of treatment. We present the market segment's economic environment, technological descriptions and issues, applications, market factors and potential, and forecasts for 2012 to 2017. We also project usage in the major primary and secondary disease application areas. This study will be of interest to the drug industry, patients, and the medical community. It will be of interest also to suppliers of products and services to this market area.

INTENDED AUDIENCE

The intended audience for this report is the pharmaceutical and biotechnology industries and diagnostics, as well as the medical industry that treats patients in these areas.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this research report. We present an analysis, by each disease area, of the number of current patients. Then, based on our surveys, we analyze the potential applications for pharmaceuticals, and forecast markets for 2012 through 2017.

INFORMATION SOURCES

BCC surveyed approximately 50 companies to obtain data for this study. Included were drug development and diagnostics companies and medical professionals. We also spoke with patients affected by memory and cognition diseases. In addition, we compiled data from current financial and trade information, and government sources.

ANALYST CREDENTIALS

Yogita Zutshi has 14 years of industry experience working in the areas of clinical and market research in the pharmaceutical area. She has an MS in Organic Chemistry, an MS in Clinical Research and a Bachelor's in Education. She has also worked on research projects in clinical data management, and developed training modules for the clinical and pharmacovigilance areas.

TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 2
STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THIS STUDY 2
SCOPE OF REPORT 2
INTENDED AUDIENCE 2
METHODOLOGY 2
INFORMATION SOURCES 3
ANALYST CREDENTIALS 3
RELATED BCC REPORTS 3
BCC ONLINE SERVICES 3
DISCLAIMER 4
CHAPTER 2 SUMMARY 6
SUMMARY 6
SUMMARY TABLE GLOBAL MARKET FOR ALZHEIMER'S DISEASE, THROUGH 2017 ($
MILLIONS) 6
SUMMARY FIGURE GLOBAL MARKET FOR ALZHEIMER'S DISEASE, 2011-2017 ($
MILLIONS) 7
FORECAST SUMMARY 7
DRIVERS FOR THE ALZHEIMER'S DISEASE MARKET 8
BARRIERS FOR THE ALZHEIMER'S DISEASE MARKET 8

CHAPTER 3 OVERVIEW 10
DEFINITION AND MARKET STRUCTURE 10
WHAT IS ALZHEIMER'S DISEASE? 10
TABLE 1 U.S. ALZHEIMER'S PATIENTS, 2002-2050 (MILLIONS) 10
FIGURE 1 U.S. ALZHEIMER'S PATIENTS, 2002-2050 (MILLIONS) 10
Role of the Cholinergic System 11
Role of Beta-Amyloid Protein 11
Behavioral Manifestations of AD 12
INCIDENCE AND PREVALENCE 13
TABLE 2 POPULATION BY SELECTED GEOGRAPHIC REGION, 2011-2050 (MILLIONS) 13
TABLE 3 PERCENT POPULATION OVER 65 BY REGION, 2011 (%) 13
TABLE 4 PEOPLE WITH ALZHEIMER'S DISEASE BY AGE GROUP, 2004-2050
(MILLIONS) 14
FIGURE 2 PEOPLE WITH ALZHEIMER'S DISEASE BY AGE GROUP 2004-2050 14
TABLE 5 PERCENTAGE OF PEOPLE WITH ALZHEIMER'S, BY AGE BRACKET, 60-94 (%) 14
FIGURE 3 PERCENTAGE OF PEOPLE WITH ALZHEIMER'S, BY AGE BRACKET, 60-94
(%) 14
TABLE 6 GLOBAL DISEASE PREVALENCE: ALZHEIMER'S DISEASE (%) 15
STAGES OF ALZHEIMER'S DISEASE 15
The Seven Stages 16

No Cognitive Decline 16
Very Mild Cognitive Decline (Occasionally Referred to as Mild
Cognitive Impairment) 16
Mild Cognitive Decline (Early Confused Stage): Losses or
Changes in the Ability to: 16
Moderate Cognitive Decline (Late Confusional Stage): 16
Moderately Severe Cognitive Decline (Early Dementia Phase): 17
Severe Cognitive Decline (Dementia): 17
Very Severe Cognitive Decline (Late Dementia or End Stage): 17
DIAGNOSIS 18
TABLE 7 DIAGNOSTIC TESTS 18
Exit 25 (Executive Interview) 19
Clock Drawing Test (CDT) 19
Urinalysis 19
Dipsticks Used in Urinalysis 20
Functional Assessment Staging Test (Fast) 20
EP-AD 20
How Accurate are the Screening Tests? 20
KEY EVENTS 22
PATENT EXPIRATIONS 22
NEW PRODUCT LAUNCHES 22
PRICING 22
KEY MARKETS 22
TABLE 8 GLOBAL MARKET FOR ALZHEIMER'S DISEASE BY REGION, THROUGH 2017
($ MILLIONS) 23
FIGURE 4 GLOBAL MARKET FOR ALZHEIMER'S DISEASE, BY REGION, 2011-2017 ($
MILLIONS) 23

MARKET SIZE AND KEY PLAYERS 23
Therapeutics 24
TABLE 9 EXISTING TREATMENTS FOR ALZHEIMER'S DISEASE 24
TABLE 10 GLOBAL EXISTING MARKET FOR SYMPTOM-ADDRESSING ALZHEIMER'S
DISEASE BY TYPE, 2010-2017 ($ MILLIONS) 25
TABLE 11 ESTIMATED GLOBAL MARKET FOR ALZHEIMER'S DRUG CLASSES BY
GEOGRAPHICAL REGION (U.S., EUROPE, JAPAN, OTHERS), 2012 ($ MILLIONS) 25
TABLE 12 TYPES OF DRUGS USED TO TREAT ALZHEIMER'S DISEASE 26
TABLE 13 MARKET SHARE OF EXISTING THERAPEUTICS FOR ALZHEIMER'S DISEASE,
2011 (%) 26
TABLE 14 BREAKDOWN OF TREATMENT MARKET BY DISEASE SEVERITY (%) 27
TABLE 15 DEMENTIA RATE BY UNDERLYING DISEASE (%) 27
TABLE 16 PERCENT OF PATIENTS WITH DEMENTIA/COGNITIVE DEFICIT (%) 27
TABLE 17 GLOBAL TREATMENT OF ALZHEIMER'S DISEASE, THROUGH 2017 ($
MILLIONS) 28
FIGURE 5 GLOBAL TREATMENT OF ALZHEIMER'S DISEASE, 2010-2017 ($ MILLIONS) 28
TABLE 18 GLOBAL POTENTIAL MARKET FOR MEMORY/COGNITION THERAPEUTICS,
THROUGH 2017 ($ MILLIONS) 29
FIGURE 6 GLOBAL MEMORY/COGNITION THERAPEUTICS MARKET BY DISEASE AREA,
2011 (%) 29
KEY PLAYERS 30
TABLE 19 MARKET SHARE OF TOP COMPANIES WORKING IN MEMORY AND
COGNITION (%) 30
TABLE 20 MARKETED TREATMENTS FOR ALZHEIMER'S DISEASE 31
DRIVERS 31
ISSUES AND CHALLENGES 31
IMAGING AND DIAGNOSTICS 32

Current Use in Alzheimer's Disease 32
Diagnostic Testing Segments 33
Imaging 33
TABLE 21 IMAGING MARKET, 2012 ($ MILLIONS) 33
FIGURE 7 IMAGING MARKET, 2012 ($ MILLIONS) 34
Standardization Needed 34
Diagnostics 35
Novel Imaging Agents 36
Opportunities for Biomarkers in AD 36
TABLE 22 BIOMARKERS FOR ALZHEIMER'S DISEASE 37
TABLE 23 GLOBAL MARKET FOR BIOMARKERS IN CLINICAL TRIALS, THROUGH 2017
($ MILLIONS) 38
FIGURE 8 GLOBAL MARKET FOR BIOMARKERS IN CLINICAL TRIALS, 2011-2017 ($
MILLIONS) 39
Testing Hypotheses 41
DIAGNOSTIC TESTS 41
KEY PLAYERS 42
AGILENT TECHNOLOGIES 42
BIOSCAN 43
CAPINTEC INC. 43
DIGIRAD CORPORATION 43
GAMMA MEDICA-IDEAS 43
GE HEALTHCARE 44
HITACHI MEDICAL SYSTEMS AMERICA INC. 44
NYMOX 44
OPTOSONICS INC. 45

PHILIPS HEALTHCARE 45
POSITRON CORP. 46
SIEMENS HEALTHCARE 46
SPECTRUM DYNAMICS LTD. 46
TOSHIBA MEDICAL SYSTEMS 47
ULTRASPECT LTD. 47
VISEN MEDICAL INC. 47
ZECOTEK IMAGING SYSTEMS 48
DRIVERS 48
ISSUES AND CHALLENGES 48
SWOT ANALYSIS 49
TABLE 24 SWOT ANALYSIS OF EXISTING ALZHEIMER'S DISEASE MARKET AND
PLAYERS 49
CHAPTER 4 TECHNOLOGIES AND APPLICATIONS 51
COMMON MECHANISMS OF ACTION 51
CHOLINESTERASE INHIBITORS 51
TABLE 25 CHOLINESTERASE INHIBITORS 52
TABLE 26 PRODUCT SIDE EFFECT COMPARISON (%) 53
FIGURE 9 PRODUCT SIDE EFFECT COMPARISON (%) 53
TABLE 27 VACCINES 54
TABLE 28 ANTI-OXIDANTS 54
NMDA ANTAGONISTS 54
TABLE 29 NMDA ANTAGONISTS 54
NICOTINICS 55
TABLE 30 NICOTINIC ACETYLCHOLINE ANTAGONISTS 55
CALCINEURINS 55
TABLE 31 CALCINEURINS 56

GABA MODULATORS 56
TABLE 32 ANTI-EPILEPTIC/GABA MODULATORS 56
HORMONES 57
TABLE 33 HORMONES 57
OTHER THERAPEUTIC MECHANISMS 57
TABLE 34 OTC TREATMENTS/NATURAL PRODUCTS 58
IMAGING AND DIAGNOSTICS: MODALITIES AND APPLICATIONS 58
NUCLEAR MEDICINE 59
POSITRON EMISSION TOMOGRAPHY (PET) 60
SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) 61
GAMMA CAMERAS 61
CT (COMPUTED TOMOGRAPHY) 61
DEXA 61
MRI (MAGNETIC RESONANCE IMAGING) 62
ULTRASOUND 63
X-RAY 63
FUSION IMAGING 64
PET/CT 64
SPECT-CT 65

SPECT-CT in Cardiology 65
SPECT-CT in General Nuclear Medicine 66
SPECT-CT in Neurology 66
DIAGNOSTIC IMAGING IN ALZHEIMER'S 66
DISEASE-MODIFYING VS. TREATMENT OF SYMPTOMS 66
SYMPTOMATIC RELIEF-LIFE-CYCLE MANAGEMENT OF EXISTING PRODUCTS 67
OTHER DRUGS TARGETING SYMPTOMATIC RELIEF 67
DRUG RE-PURPOSING 68
GENERICS 68
CHAPTER 5 WORLDWIDE INDUSTRY STRUCTURE 70
GROWTH DRIVERS 70
AGING POPULATION 70
OFF-LABEL USE 70
UNDERSTANDING OF MECHANISMS 71
TRANSCRANIAL MAGNETIC STIMULATION 72
GENETIC MODIFICATIONS 72
GROWTH OBSTACLES 72
UNDERSTANDING OF MECHANISM 73
TABLE 35 CLINICAL SUCCESS RATES BY THERAPEUTIC AREA (%) 73

CO-MORBID DISEASE STATES 73
KEY COMPETITIVE FACTORS 73
PRODUCT LAUNCH 74
LIFE CYCLE MANAGEMENT 74
PAYERS 74
INTERNATIONAL ASPECTS 75
TABLE 36 PERCAPITA GOVERNMENT EXPENDITURE ON HEALTHCARE BY COUNTRY,
THROUGH 2010 ($ MILLIONS) 76
CHAPTER 6 LEGISLATION AND REGULATORY ENVIRONMENT 79
VALIDATED TARGETS 79
LACK OF BIOMARKERS 79
TRANSLATIONAL MEDICINE 80
REIMBURSEMENT 80
CHAPTER 7 RELATED DEALS AND PARTNERSHIPS 83
APPROACH 83
DIAGNOSTICS DEALS 83
OVERALL ACTIVITY 84
TABLE 37 DEALS AND PARTNERSHIPS, 2005-2012 84
CHAPTER 8 PIPELINE 88
TABLE 38 DEVELOPMENT PIPELINE OF ALZHEIMER'S DRUGS, BY PHASE 89
FIGURE 10 DEVELOPMENT PIPELINE OF ALZHEIMER'S DRUGS: NUMBER OF
PROGRAMS AT EACH CLINICAL PHASE 95
CHAPTER 9 TRENDS AND CHALLENGES 98
AWARENESS OF ALZHEIMER'S 98
DISEASE PATHWAYS BEING ELUCIDATED 98
MANY PROGRAMS IN DEVELOPMENT 98
TABLE 39 SOME NOT-FOR-PROFIT ORGANIZATIONS AND CONSORTIA IN THE AD
AREA 99
TABLE 40 INVESTMENT IN ALZHEIMER'S DISEASE COMPANIES, 2008-2012 101
CHAPTER 10 OUTLOOK 104

A VARIETY OF APPROACHES IN RESEARCH 104
MANY PROGRAMS IN DEVELOPMENT 105
CHAPTER 11 PATENT ANALYSIS 107
TABLE 41 KEY PATENT EXPIRY: ALZHEIMER'S THERAPEUTICS, BY CATEGORY
THERAPEUTICS AND TECHNOLOGIES 107
TABLE 42 MAJOR U.S. PATENT HOLDERS/FILERS IN ALZHEIMER'S 108
TABLE 43 PATENTS ISSUED, 2011-2012 108
TABLE 44 PATENT APPLICATIONS 128
CHAPTER 12 COMPANY PROFILES 149
ABBOTT LABORATORIES 149
ABLYNX 149
ACCERA, INC. 149
ACUMEN PHARMACEUTICALS 152
ADAMAS PHARMACEUTICALS 152
AFFIRIS AG 153
AFFITECH AS 153
ALLON THERAPEUTICS (FKA NEURODISCOVERY) 154
ALZHYME PTY 154
ASTELLAS 154
ASTRAZENECA 155
ATHENA DIAGNOSTICS (THERMO FISHER) 155
AVERA PHARMACEUTICALS 156
BAXTER INTERNATIONAL INC. (BAXTER) 156
BAYER HEALTHCARE PHARMA 157
BELLUS HEALTH 157
BIOFUTURA 158

BIOMERIEUX 158
BIOVAIL 158
BOEHRINGER INGELHEIM 159
BRACCO 159
BRAINCELLS, INC. 159
BRISTOL MYERS SQUIBB 159
CELLZOME 160
CEREGENE 160
COGNITION PHARMACEUTICALS LLC 160
COGNITION THERAPEUTICS 161
COLUCID PHARMACEUTICALS 161
COMENTIS 161
CORTEX PHARMACEUTICALS 162
C2N DIAGNOSTICS 162
CYTOS BIOTECHNOLOGY 162
DAIICHI SANKYO 163
DEBIOPHARM 163
DURECT 163
EISAI 164
ELAN 165
ELI LILLY 165
ENVIVO PHARMACEUTICALS 165
ESTEVE 166
EVOTEC 166
EXONHIT THERAPEUTICS 167

FOREST LABORATORIES 167
GALANTOS PHARMA 168
GALENEA 168
GE HEALTHCARE 168
GLAXOSMITH KLINE 169
HELICON THERAPEUTICS 169
INTELLECT NEUROSCIENCES 169
INTRA-CELLULAR THERAPIES 170
INVERNESS MEDICAL INNOVATIONS 170
IPSEN 171
JOHNSON & JOHNSON 171
KEYNEUROTEK 172
LEXICON PHARMACEUTICALS 172
LINK MEDICINE 172
LUNDBECK 173
MEDIVATION 173
MEMORY PHARMACEUTICALS 174
MERCK 174
MERCKSERONO 174
MERZ PHARMA 175
MITHRIDION 175
MITSUBISHI TANABE 175
MORPHOSYS 176
NEUREN PHARMACEUTICALS 176
NEUROPTIX (COGNOPTIX, INC) 177

NEUROSEARCH 177
NEURO-HITECH 178
NEWRON PHARMACEUTICALS 178
NOSCIRA SA 178
NOVARTIS AG 179
NYMOX 179
OLIGOMERIX 180
ORTHO-MCNEIL NEUROLOGICS 180
PFIZER 180
POWER3 MEDICAL PRODUCTS 181
PRANA BIOTECHNOLOGY 182
PROTEOTECH INC. 182
PSYCHOGENICS 182
ROCHE 183
REPROCELL 183
SAMARITAN PHARMACEUTICALS 184
SANOFI-AVENTIS 184
SATORI PHARMACEUTICALS 184
SATORIS 185
SCIELE PHARMA 185
SIEMENS MEDICAL SOLUTIONS 186
SOLVAY 186
SUVEN LIFE SCIENCE 186
TAKEDA 187
TARGACEPT 187
TAURX THERAPEUTICS 187
TAUTATIS 188

TEIKOKU 188
TEVA PHARMACEUTICALS 189
TRANSTECH PHARMA 189
VALEANT PHARMACEUTICALS 190
VOYAGER PHARMACEUTICAL / DURAMED 190
WATSON PHARMACEUTICALS 190
WYETH/PFIZER 190

LIST OF TABLES
SUMMARY TABLE GLOBAL MARKET FOR ALZHEIMER'S DISEASE, THROUGH 2017 ($
MILLIONS) 6
TABLE 1 U.S. ALZHEIMER'S PATIENTS, 2002-2050 (MILLIONS) 10
TABLE 2 POPULATION BY SELECTED GEOGRAPHIC REGION, 2011-2050 (MILLIONS) 13
TABLE 3 PERCENT POPULATION OVER 65 BY REGION, 2011 (%) 13
TABLE 4 PEOPLE WITH ALZHEIMER'S DISEASE BY AGE GROUP, 2004-2050 (MILLIONS) 14
TABLE 5 PERCENTAGE OF PEOPLE WITH ALZHEIMER'S, BY AGE BRACKET, 60-94 (%) 14
TABLE 6 GLOBAL DISEASE PREVALENCE: ALZHEIMER'S DISEASE (%) 15
TABLE 7 DIAGNOSTIC TESTS 18
TABLE 8 GLOBAL MARKET FOR ALZHEIMER'S DISEASE BY REGION, THROUGH 2017
($ MILLIONS) 23
TABLE 9 EXISTING TREATMENTS FOR ALZHEIMER'S DISEASE 24
TABLE 10 GLOBAL EXISTING MARKET FOR SYMPTOM-ADDRESSING ALZHEIMER'S
DISEASE BY TYPE, 2010-2017 ($ MILLIONS) 25
TABLE 11 ESTIMATED GLOBAL MARKET FOR ALZHEIMER'S DRUG CLASSES BY
GEOGRAPHICAL REGION (U.S., EUROPE, JAPAN, OTHERS), 2012 ($ MILLIONS) 25
TABLE 12 TYPES OF DRUGS USED TO TREAT ALZHEIMER'S DISEASE 26
TABLE 13 MARKET SHARE OF EXISTING THERAPEUTICS FOR ALZHEIMER'S DISEASE,
2011 (%) 26
TABLE 14 BREAKDOWN OF TREATMENT MARKET BY DISEASE SEVERITY (%) 27
TABLE 15 DEMENTIA RATE BY UNDERLYING DISEASE (%) 27
TABLE 16 PERCENT OF PATIENTS WITH DEMENTIA/COGNITIVE DEFICIT (%) 27
TABLE 17 GLOBAL TREATMENT OF ALZHEIMER'S DISEASE, THROUGH 2017 ($
MILLIONS) 28

TABLE 18 GLOBAL POTENTIAL MARKET FOR MEMORY/COGNITION THERAPEUTICS,
THROUGH 2017 ($ MILLIONS) 29
TABLE 19 MARKET SHARE OF TOP COMPANIES WORKING IN MEMORY AND
COGNITION (%) 30
TABLE 20 MARKETED TREATMENTS FOR ALZHEIMER'S DISEASE 31
TABLE 21 IMAGING MARKET, 2012 ($ MILLIONS) 33
TABLE 22 BIOMARKERS FOR ALZHEIMER'S DISEASE 37
TABLE 23 GLOBAL MARKET FOR BIOMARKERS IN CLINICAL TRIALS, THROUGH 2017
($ MILLIONS) 38
TABLE 24 SWOT ANALYSIS OF EXISTING ALZHEIMER'S DISEASE MARKET AND
PLAYERS 49
TABLE 25 CHOLINESTERASE INHIBITORS 52
TABLE 26 PRODUCT SIDE EFFECT COMPARISON (%) 53
TABLE 27 VACCINES 54
TABLE 28 ANTI-OXIDANTS 54
TABLE 29 NMDA ANTAGONISTS 54
TABLE 30 NICOTINIC ACETYLCHOLINE ANTAGONISTS 55
TABLE 31 CALCINEURINS 56
TABLE 32 ANTI-EPILEPTIC/GABA MODULATORS 56
TABLE 33 HORMONES 57
TABLE 34 OTC TREATMENTS/NATURAL PRODUCTS 58
TABLE 35 CLINICAL SUCCESS RATES BY THERAPEUTIC AREA (%) 73
TABLE 36 PERCAPITA GOVERNMENT EXPENDITURE ON HEALTHCARE BY COUNTRY,
THROUGH 2010 ($ MILLIONS) 76
TABLE 37 DEALS AND PARTNERSHIPS, 2005-2012 84
TABLE 38 DEVELOPMENT PIPELINE OF ALZHEIMER'S DRUGS, BY PHASE 89
TABLE 39 SOME NOT-FOR-PROFIT ORGANIZATIONS AND CONSORTIA IN THE AD
AREA 99
TABLE 40 INVESTMENT IN ALZHEIMER'S DISEASE COMPANIES, 2008-2012 101
TABLE 41 KEY PATENT EXPIRY: ALZHEIMER'S THERAPEUTICS, BY CATEGORY
THERAPEUTICS AND TECHNOLOGIES 107
TABLE 42 MAJOR U.S. PATENT HOLDERS/FILERS IN ALZHEIMER'S 108
TABLE 43 PATENTS ISSUED, 2011-2012 108
TABLE 44 PATENT APPLICATIONS 128

LIST OF FIGURES
SUMMARY FIGURE GLOBAL MARKET FOR ALZHEIMER'S DISEASE, 2011-2017 ($
MILLIONS) 7
FIGURE 1 U.S. ALZHEIMER'S PATIENTS, 2002-2050 (MILLIONS) 10
FIGURE 2 PEOPLE WITH ALZHEIMER'S DISEASE BY AGE GROUP 2004-2050 14
FIGURE 3 PERCENTAGE OF PEOPLE WITH ALZHEIMER'S, BY AGE BRACKET, 60-94 (%) 14
FIGURE 4 GLOBAL MARKET FOR ALZHEIMER'S DISEASE, BY REGION, 2011-2017 ($
MILLIONS) 23
FIGURE 5 GLOBAL TREATMENT OF ALZHEIMER'S DISEASE, 2010-2017 ($ MILLIONS) 28
FIGURE 6 GLOBAL MEMORY/COGNITION THERAPEUTICS MARKET BY DISEASE AREA,
2011 (%) 29
FIGURE 7 IMAGING MARKET, 2012 ($ MILLIONS) 34
FIGURE 8 GLOBAL MARKET FOR BIOMARKERS IN CLINICAL TRIALS, 2011-2017 ($
MILLIONS) 39
FIGURE 9 PRODUCT SIDE EFFECT COMPARISON (%) 53
FIGURE 10 DEVELOPMENT PIPELINE OF ALZHEIMER'S DRUGS: NUMBER OF
PROGRAMS AT EACH CLINICAL PHASE 95

Read the full report:
Alzheimer%s Disease Therapeutics and Diagnostics: Global Markets

http://www.reportbuyer.com/pharma_healthcare/diseases/alzheimer/alzheimers_disease_therapeutics_diagnostics_global_markets.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com  
Email: query@reportbuyer.com  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
News On 6
303 N. Boston Ave.
Tulsa, OK 74103
TULSA'S OWN TM
GREEN COUNTRY'S OWN TM
Oklahoma's Own Newson6.com is proud to provide Oklahomans with timely and relevant news and information, sharing the stories, pictures and loves of Oklahomans across our great state including Tulsa's Own and Green Country's Own.
All content © Copyright 2000 - 2014, WorldNow and KOTV. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.